Gilead Partnership With Arcus Brings PD-1, TIGIT Assets To Its IO Portfolio
The 10-year partnership brings Arcus up-front funding with ample earnout opportunities, while Gilead gets extensive opt-in rights and an equity stake it can increase – and potentially a wholly owned dual checkpoint combination.
You may also be interested in...
Gilead is licensing two anti-TIGIT candidates and a pair of adenosine pathway-targeted drugs. The firms will study various IO combo regimens, possibly including Gilead drugs like Trodelvy.
The company’s two approved cell therapies led growth in oncology. But despite oncology currently accounting for a small share of Gilead’s overall business, analysts expect big readouts later in the year.
Arcus Biosciences has one of the most advanced TIGIT programs, but early data were not strong enough to convince partner Gilead to commit to funding pivotal studies just yet